FR2984359B1 - METHOD FOR THE DIAGNOSIS OR PROGNOSIS, IN VITRO, OF PROSTATE CANCER - Google Patents
METHOD FOR THE DIAGNOSIS OR PROGNOSIS, IN VITRO, OF PROSTATE CANCERInfo
- Publication number
- FR2984359B1 FR2984359B1 FR1162027A FR1162027A FR2984359B1 FR 2984359 B1 FR2984359 B1 FR 2984359B1 FR 1162027 A FR1162027 A FR 1162027A FR 1162027 A FR1162027 A FR 1162027A FR 2984359 B1 FR2984359 B1 FR 2984359B1
- Authority
- FR
- France
- Prior art keywords
- prognosis
- vitro
- diagnosis
- prostate cancer
- prostate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010060862 Prostate cancer Diseases 0.000 title 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 238000000338 in vitro Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000004393 prognosis Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1162027A FR2984359B1 (en) | 2011-12-20 | 2011-12-20 | METHOD FOR THE DIAGNOSIS OR PROGNOSIS, IN VITRO, OF PROSTATE CANCER |
| US14/367,635 US11459605B2 (en) | 2011-12-20 | 2012-12-18 | Method for the diagnosis or prognosis, in vitro, of prostate cancer |
| PCT/FR2012/052970 WO2013093324A2 (en) | 2011-12-20 | 2012-12-18 | Method for the diagnosis or prognosis, in vitro, of prostate cancer |
| ES12819084.0T ES2659556T3 (en) | 2011-12-20 | 2012-12-18 | Procedure for the diagnosis, in vitro, of prostate cancer |
| EP12819084.0A EP2794923B8 (en) | 2011-12-20 | 2012-12-18 | Method for the diagnosis in vitro of prostate |
| CN201280063390.6A CN104024434B (en) | 2011-12-20 | 2012-12-18 | In-vitro diagnosis or the method for prognosis for carcinoma of prostate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1162027A FR2984359B1 (en) | 2011-12-20 | 2011-12-20 | METHOD FOR THE DIAGNOSIS OR PROGNOSIS, IN VITRO, OF PROSTATE CANCER |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2984359A1 FR2984359A1 (en) | 2013-06-21 |
| FR2984359B1 true FR2984359B1 (en) | 2017-11-24 |
Family
ID=47628302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR1162027A Expired - Fee Related FR2984359B1 (en) | 2011-12-20 | 2011-12-20 | METHOD FOR THE DIAGNOSIS OR PROGNOSIS, IN VITRO, OF PROSTATE CANCER |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11459605B2 (en) |
| EP (1) | EP2794923B8 (en) |
| CN (1) | CN104024434B (en) |
| ES (1) | ES2659556T3 (en) |
| FR (1) | FR2984359B1 (en) |
| WO (1) | WO2013093324A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2984362B1 (en) * | 2011-12-20 | 2017-11-24 | Biomerieux Sa | METHOD FOR IN VITRO DIAGNOSIS OR PROGNOSIS OF LUNG CANCER |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US87436A (en) * | 1869-03-02 | Improvement in prttning-shbars | ||
| US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| EP1415005B1 (en) * | 2000-12-07 | 2012-11-21 | Novartis Vaccines and Diagnostics, Inc. | Endogenous retroviruses up-regulated in prostate cancer |
| US20040009481A1 (en) * | 2001-06-11 | 2004-01-15 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer |
| AU2002351332A1 (en) * | 2001-12-07 | 2003-06-23 | Chiron Corporation | Endogenous retrovirus polypeptides linked to oncogenic transformation |
| FR2984362B1 (en) * | 2011-12-20 | 2017-11-24 | Biomerieux Sa | METHOD FOR IN VITRO DIAGNOSIS OR PROGNOSIS OF LUNG CANCER |
-
2011
- 2011-12-20 FR FR1162027A patent/FR2984359B1/en not_active Expired - Fee Related
-
2012
- 2012-12-18 WO PCT/FR2012/052970 patent/WO2013093324A2/en not_active Ceased
- 2012-12-18 US US14/367,635 patent/US11459605B2/en active Active
- 2012-12-18 ES ES12819084.0T patent/ES2659556T3/en active Active
- 2012-12-18 EP EP12819084.0A patent/EP2794923B8/en active Active
- 2012-12-18 CN CN201280063390.6A patent/CN104024434B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US11459605B2 (en) | 2022-10-04 |
| WO2013093324A3 (en) | 2013-12-19 |
| FR2984359A1 (en) | 2013-06-21 |
| WO2013093324A2 (en) | 2013-06-27 |
| US20140370503A1 (en) | 2014-12-18 |
| ES2659556T3 (en) | 2018-03-16 |
| EP2794923B1 (en) | 2017-09-20 |
| EP2794923A2 (en) | 2014-10-29 |
| CN104024434A (en) | 2014-09-03 |
| EP2794923B8 (en) | 2018-03-21 |
| CN104024434B (en) | 2016-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2831281A4 (en) | MOLECULAR MARKERS FOR THE PREDICTION OF PROSTATE CANCER PROGNOSIS, METHOD AND KIT THEREOF | |
| FR2944019B1 (en) | METHOD FOR DETERMINING PRODEFENSIN-A6 FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER | |
| EP2825669A4 (en) | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA | |
| EP2776830A4 (en) | METHOD OF PREDICTING THE PROGNOSIS OF BREAST CANCER | |
| EP2687796A4 (en) | REFRIGERATOR, AND APPARATUS AND METHOD FOR REFRIGERATOR DIAGNOSIS | |
| EP4036119C0 (en) | ANTIBODIES AGAINST CLAUDIN 18.2 USEFUL FOR CANCER DIAGNOSIS | |
| HK1199100A1 (en) | Methods and compositions for the treatment and diagnosis of colorectal cancer | |
| EP2828405A4 (en) | PANEL OF MARKERS FOR THE DETECTION OF CANCER | |
| GB2513275B (en) | Biomarkers for Breast Cancer Prediction and Diagnosis | |
| HK1202313A1 (en) | Methods and compositions for the treatment and diagnosis of bladder cancer | |
| ZA201300519B (en) | Novel antibody for the diagnosis and/or prognosis of cancer | |
| EP2698634A4 (en) | BIOMARKER FOR BREAST CANCER | |
| EP2524702A4 (en) | DIAGNOSIS FOR CANCER | |
| ZA201401326B (en) | Novel anti-cxcr4 antibody and its use for the detection and diagnosis of cancer | |
| EP2988131A4 (en) | Genetic marker for early breast cancer prognosis prediction and diagnosis, and use thereof | |
| EP2825886A4 (en) | MEANS AND METHODS FOR THE DIAGNOSIS AND THERAPEUTICS OF DISEASES | |
| EP2785871A4 (en) | CTC BIOMARKER ASSAY FOR COMBAT BREAST CANCER BRAIN METASTASIS | |
| EP2515114A4 (en) | METHOD FOR THE DIAGNOSIS OF MALIGNANT TUMOR | |
| EP2773774A4 (en) | BIOMARKERS FOR THE TREATMENT OF TSLP | |
| SG11201402115TA (en) | Methods for diagnosis and/or prognosis of gynecological cancer | |
| PL2444811T3 (en) | Methods for the diagnosis or prognosis of colorectal cancer | |
| EP2880443A4 (en) | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND PROGNOSIS OF BREAST CANCER | |
| LT2672994T (en) | Anti-alpha-v integrin antibody for the treatment of prostate cancer | |
| FR2969616B1 (en) | PROCESS FOR THE PREPARATION OF CARBENIC PLATINUM COMPLEXES | |
| FR2961810B1 (en) | METRONIDAZOLE ESTERS FOR TREATING ROSACEA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PLFP | Fee payment |
Year of fee payment: 5 |
|
| PLFP | Fee payment |
Year of fee payment: 6 |
|
| PLFP | Fee payment |
Year of fee payment: 7 |
|
| PLFP | Fee payment |
Year of fee payment: 8 |
|
| PLFP | Fee payment |
Year of fee payment: 9 |
|
| PLFP | Fee payment |
Year of fee payment: 10 |
|
| PLFP | Fee payment |
Year of fee payment: 11 |
|
| ST | Notification of lapse |
Effective date: 20230808 |